Given that CREB is activated by cAMP, they nominated CREB as one of the candidate therapeutic targets, demonstrating synergistic tumor cell inhibition when CREB inhibitor was combined with chemotherapies doxorubicin and paclitaxel. This evidence concerns the gene CREB1 and neoplasm.